These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Chang MH; Gordon LA; Fung HB Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763 [TBL] [Abstract][Full Text] [Related]
4. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Foote BS; Spooner LM; Belliveau PP Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346 [TBL] [Abstract][Full Text] [Related]
5. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A; Serfaty L J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [TBL] [Abstract][Full Text] [Related]
6. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Trembling PM; Tanwar S; Dusheiko GM Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560 [TBL] [Abstract][Full Text] [Related]
7. Telaprevir for the treatment of chronic hepatitis C infection. Muir AJ Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK; Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693 [TBL] [Abstract][Full Text] [Related]
10. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964 [No Abstract] [Full Text] [Related]
12. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191 [TBL] [Abstract][Full Text] [Related]
13. Investigational drugs for hepatitis C. Flisiak R; Parfieniuk A Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555 [TBL] [Abstract][Full Text] [Related]
14. [New agents for the treatment of hepatitis C]. Buti M; Homs M Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805 [TBL] [Abstract][Full Text] [Related]
15. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C. Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712 [No Abstract] [Full Text] [Related]
16. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR; Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609 [TBL] [Abstract][Full Text] [Related]
17. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice]. Crespo J; Berenguer M; Pérez F; Fernández I; González O; Bárcena R; Buti M; López J; Calleja JL; Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446 [TBL] [Abstract][Full Text] [Related]